Jean Mack predicts Phase 2 will enroll patients across Australia, potentially Europe, and the United States
“we'll also include The US now, as well as potentially some European centers as well. So we can enroll this study quick as quickly as possible. So we'll be in Australia, potentially a couple of centers in Europe, and then definitely in The United States for our phase two study.”
→ Read the source episode
Our resolution criterion
disputablePhase 2 study sites are established and actively enrolling in Australia, US, and at least one European country
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Laurent Levy predicts Nanobiotics will complete pancreatic, melanoma, and esophageal cancer trials before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.